naion with semaglutide use in patients diabetes was associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) at 2, 3, and 4 years. https://ja.ma/4iZkMeV Semaglutide-suspected NAION cases reported globally

Houman, body fat is actively working to lower T production

Consult a licensed physician before making any decision about GLP-1 therapy

Like GLP-1, GIP is involved in metabolic signaling

This review summarizes the relevant aspects of gut microbiota metabolism, explores how these gut microbiota-derived metabolites regulate cancer progression through ferroptosis, and proposes that targeting gut microbiota-mediated ferroptosis represents a potential therapeutic approach for gastrointestinal tumors

Deluxe HydraFacial This customizable HydraFacial is designed to treat a variety of skin concerns, including fine lines, loss of elasticity, acne, and dullness

[PMID 38958939, PMID 39976940, PMID 42060879] CONTRAINDICATIONS A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy PRECAUTIONS Kidney disease No dose adjustment is necessary for any degree of renal impairment Liver disease No dose adjustment is necessary for any degree of hepatic impairment Stomach disorders Wegovy slows gastric emptying and is not recommended in patients with significant stomach disorders, including diabetic gastroparesis General anesthesia or deep sedation GLP-1 therapies, like Wegovy, slow gastric emptying, possibly increasing the risk of residual gastric contents and pulmonary aspiration in patients receiving anesthesia or deep sedation for procedures